AU2016290654C1 - Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts - Google Patents

Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts Download PDF

Info

Publication number
AU2016290654C1
AU2016290654C1 AU2016290654A AU2016290654A AU2016290654C1 AU 2016290654 C1 AU2016290654 C1 AU 2016290654C1 AU 2016290654 A AU2016290654 A AU 2016290654A AU 2016290654 A AU2016290654 A AU 2016290654A AU 2016290654 C1 AU2016290654 C1 AU 2016290654C1
Authority
AU
Australia
Prior art keywords
formula
compound
salt
crystalline form
side chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016290654A
Other languages
English (en)
Other versions
AU2016290654A1 (en
AU2016290654B2 (en
AU2016290654A2 (en
Inventor
Martin Bohlin
Chantal Devin
Sébastien Rocchi
Wei Tian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mimetogen Pharmaceuticals Inc
Original Assignee
Mimetogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mimetogen Pharmaceuticals Inc filed Critical Mimetogen Pharmaceuticals Inc
Publication of AU2016290654A1 publication Critical patent/AU2016290654A1/en
Publication of AU2016290654A2 publication Critical patent/AU2016290654A2/en
Application granted granted Critical
Publication of AU2016290654B2 publication Critical patent/AU2016290654B2/en
Publication of AU2016290654C1 publication Critical patent/AU2016290654C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016290654A 2015-07-09 2016-07-08 Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts Active AU2016290654C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190596P 2015-07-09 2015-07-09
US62/190,596 2015-07-09
PCT/EP2016/066281 WO2017005902A1 (en) 2015-07-09 2016-07-08 Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts

Publications (4)

Publication Number Publication Date
AU2016290654A1 AU2016290654A1 (en) 2018-01-25
AU2016290654A2 AU2016290654A2 (en) 2020-08-06
AU2016290654B2 AU2016290654B2 (en) 2021-07-08
AU2016290654C1 true AU2016290654C1 (en) 2021-11-11

Family

ID=56413639

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016290654A Active AU2016290654C1 (en) 2015-07-09 2016-07-08 Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts

Country Status (9)

Country Link
US (4) US10125165B2 (OSRAM)
EP (2) EP3319978B1 (OSRAM)
JP (1) JP6801835B2 (OSRAM)
KR (1) KR102056257B1 (OSRAM)
CN (2) CN114874288A (OSRAM)
AU (1) AU2016290654C1 (OSRAM)
CA (1) CA2991661A1 (OSRAM)
TW (1) TWI708779B (OSRAM)
WO (1) WO2017005902A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6801835B2 (ja) 2015-07-09 2020-12-16 ミメトゲン ファーマシュウティカルズ インコーポレイテッドＭｉｍｅｔｏｇｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． β−ターンペプチド模倣環状塩の液相合成及び結晶化
PL3464336T3 (pl) 2016-06-01 2022-05-16 Athira Pharma, Inc. Związki
MX2020012629A (es) * 2018-05-31 2021-01-29 Sederma Sa Metodo para sintesis de peptido en fase de solucion y estrategias protectoras de la misma.
US11427612B2 (en) * 2018-08-21 2022-08-30 Wayne State University Epimerization-free N to C solid-phase peptide synthesis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013191926A1 (en) * 2012-06-22 2013-12-27 Mimetogen Pharmaceuticals, Inc. Synthesis of beta-turn peptidomimetic cyclic compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP254898A0 (en) * 1998-03-24 1998-04-23 University Of Queensland, The Peptide turn mimetics
WO2001052843A1 (en) 2000-01-18 2001-07-26 Mcgill University β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS
BR0311558A (pt) * 2002-06-11 2007-04-27 Lilly Co Eli composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, métodos para afetar os receptores de glutamato metabotrópicos ligados a camp, para administrar uma quantidade eficaz de um composto e para tratar um distúrbio neurológico e psiquiátrico em um paciente, e, formulação farmacêutica
KR101565185B1 (ko) * 2008-04-04 2015-11-02 미메토젠 파르마슈티칼스 인크. 건안증을 치료하기 위한 베타-턴 펩티도미메틱 환상 화합물
ES2512717T3 (es) * 2009-02-27 2014-10-24 Mimetogen Pharmaceuticals Inc. Compuestos cíclicos peptidomiméticos para el tratamiento de la retinitis pigmentosa
WO2012013281A1 (de) * 2010-07-29 2012-02-02 Merck Patent Gmbh Flüssigkristallines medium enthaltend thiophenderivate
JP5710436B2 (ja) * 2011-09-26 2015-04-30 株式会社東芝 パターン形成方法
JP6516974B2 (ja) * 2013-06-14 2019-05-22 豊田合成株式会社 ゴム組成物及びゴム製品
US9200100B2 (en) * 2013-06-20 2015-12-01 Exxonmobil Chemical Patents Inc. Long-bridged salen catalyst
JP6801835B2 (ja) * 2015-07-09 2020-12-16 ミメトゲン ファーマシュウティカルズ インコーポレイテッドＭｉｍｅｔｏｇｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． β−ターンペプチド模倣環状塩の液相合成及び結晶化

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013191926A1 (en) * 2012-06-22 2013-12-27 Mimetogen Pharmaceuticals, Inc. Synthesis of beta-turn peptidomimetic cyclic compounds

Also Published As

Publication number Publication date
US11078234B2 (en) 2021-08-03
CN107849089B (zh) 2022-07-05
CN114874288A (zh) 2022-08-09
EP3319978A1 (en) 2018-05-16
US20210300966A1 (en) 2021-09-30
TW201716425A (zh) 2017-05-16
US20170008923A1 (en) 2017-01-12
EP4549450A2 (en) 2025-05-07
WO2017005902A1 (en) 2017-01-12
AU2016290654A1 (en) 2018-01-25
EP4549450A3 (en) 2025-07-02
HK1255355A1 (en) 2019-08-16
US11753441B2 (en) 2023-09-12
US20190194251A1 (en) 2019-06-27
CA2991661A1 (en) 2017-01-12
US12281179B2 (en) 2025-04-22
KR20180036982A (ko) 2018-04-10
TWI708779B (zh) 2020-11-01
KR102056257B1 (ko) 2019-12-16
JP6801835B2 (ja) 2020-12-16
CN107849089A (zh) 2018-03-27
EP3319978C0 (en) 2025-02-19
JP2018528928A (ja) 2018-10-04
EP3319978B1 (en) 2025-02-19
AU2016290654B2 (en) 2021-07-08
US20230357318A1 (en) 2023-11-09
US10125165B2 (en) 2018-11-13
AU2016290654A2 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
US12281179B2 (en) Solution phase synthesis of β-turn peptidomimetic cyclic salts
TWI873263B (zh) 胜肽化合物的合成法
JP7625531B2 (ja) 立体障害の大きなアミノ酸を含むペプチド化合物の製造方法
WO2023127869A1 (ja) Ｎ－アルキルアミノ酸、およびｎ－アルキルアミノ酸を含むペプチドの製造方法
US4638046A (en) Retro-inverso C-terminal hexapeptide analogues of substance P
DK151968B (da) Fremgangsmaade til fremstilling af pentapeptidet h-arg-x-asp-y-tyr-r ved oploesningssyntese
AU2007263805B2 (en) Pseudo proline dipeptides
HK1255355B (en) Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts
HK40081202A (en) Solution phase synthesis and crystallization of beta-turn peptidomimetic cyclic salts
Balaev et al. Synthesis of leuprorelin acetate
US9605020B2 (en) Method for producing dipeptide derivative containing disubstituted amino acid residue
RU2574392C1 (ru) СПОСОБ ПОЛУЧЕНИЯ ТРИПЕПТИДА ОБЩЕЙ ФОРМУЛЫ (I) HPyr-His-TrpOH, ИСПОЛЬЗУЕМОГО В КАЧЕСТВЕ ПРОМЕЖУТОЧНОГО СОЕДИНЕНИЯ (1-3 ФРАГМЕНТА) В СИНТЕЗЕ СИНТЕТИЧЕСКИХ АГОНИСТОВ ГОНАДОТРОПИН-РИЛИЗИНГ-ГОРМОНА (LH-RH), МЕТОДОМ ЖИДКОФАЗНОГО ПЕПТИДНОГО СИНТЕЗА БЕЗ ПОСТАНОВКИ И СНЯТИЙ ЗАЩИТНЫХ ГРУПП
Chen et al. Facile Synthesis of Biologically Active Peptides Using Phase Transfer Reagents as C‐Terminal Protecting Group
WO2024195801A1 (ja) 環状ペプチドの共結晶の製造方法
CN118475590A (zh) N-烷基氨基酸以及包含n-烷基氨基酸的肽的制造方法
US3585180A (en) Process for preparing peptides containing histidine protected with a 2,2,2,-trihalogeno - n -benzyloxycarbonylaminoethyl group
CN108864252A (zh) 制备nrx-1074的方法
DK149755B (da) Analogifremgangsmaade til fremstilling af lhrh-analoge nonapeptidamidderivater eller fysiologisk acceptable salte eller metalkomplekser deraf
PT1440977E (pt) Processo de síntese melhorado de derivados diamidas do tripéptido kpv

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ DEVIN, CHANTAL; TIAN, WEI; BOHLIN, MARTIN AND ROCCHI, SEBASTIEN

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 MAY 2020

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JUL 2021

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JUL 2021

FGA Letters patent sealed or granted (standard patent)